Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab versus bevacizumab adjunctive to Ahmed glaucoma valve implantation for neovascular glaucoma
ChiCTR-IPR-15006695Phase 4Suspended
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in neovascular glaucoma (NVG) comparing Ranibizumab group with Bevacizumab group (2 arms). Primary endpoint: Intraocular pressure. Started Jan 2016; status: suspended.
02
Drugs
ranibizumabbevacizumab
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on ChiCTR-IPR-15006695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006695.